|View printer-friendly version|
|ERYTECH Strengthens Executive Team with the Appointment of Alex Dusek as VP of Commercial Strategy|
“I am pleased to welcome Alex to the ERYTECH team at this exciting
Prior to joining ERYTECH, Mr. Dusek served as the Vice President of
Commercial Strategy at
“ERYTECH is the leader in red blood cell-based cancer therapeutics,” stated Mr. Dusek. “I’m excited to join a company with advanced clinical programs and a platform that offers the potential promise to treat patients suffering from many different serious diseases. I look forward to utilizing my broad product launch experience and assisting the team in the transformation of ERYTECH from a development company to a commercially successful operation.”
Mr. Dusek will be based in
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.
The Company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status.
Eryaspase demonstrated positive efficacy and safety results in various clinical trials in ALL, including in a Phase 2 study in patients over 55 years of age and in a Phase 2/3 trial in relapsed or refractory ALL patients, as well as in pancreatic cancer, where it achieved positive results in a Phase 2b trial of second-line treatment of patients with metastatic pancreatic cancer. ERYTECH is preparing for the launch of a pivotal Phase 3 clinical trial in second line pancreatic cancer and Phase 2 trials in first line pancreatic cancer and triple-negative breast cancer.
ERYTECH produces eryaspase at its own GMP-approved and operational
manufacturing site in Lyon (
In addition to eryaspase, ERYTECH is developing erymethionase, methionine-γ-lyase encapsulated in red blood cells, to target cancer cells’ amino acid metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).
ERYTECH is listed on the Nasdaq Global Select Market in the
This press release contains forward-looking statements, forecasts and
estimates. These statements, forecasts and estimates may be identified
by the use of words such as “anticipate,” “expect,” “will,” “believe,”
“continue,” “enable” and other similar terms and phrases. All statements
contained in this press release other than statements of historical
facts are forward-looking statements, including, without limitation
statements regarding the potential of ERYTECH’s product pipeline, its
clinical development and regulatory plans of eryaspase. Such statements,
forecasts and estimates are based on various assumptions and assessments
of known and unknown risks, uncertainties and other factors, which were
deemed reasonable when made but may or may not prove to be correct.
Actual events are difficult to predict and may depend upon factors that
are beyond ERYTECH’s control. There can be no guarantees with respect to
pipeline product candidates that the candidates will receive the
necessary regulatory approvals or that they will prove to be
commercially successful. Therefore, actual results may turn out to be
materially different from the anticipated future results, performance or
achievements expressed or implied by such statements, forecasts and
estimates. Further description of these risks, uncertainties and other
risks can be found in the Company’s regulatory filings with the French
Autorité des Marchés Financiers (AMF), the Company’s